Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Interest & Investment Income: 2010-2025

Historic Interest & Investment Income for Altimmune (ALT) over the last 12 years, with Sep 2025 value amounting to $2.4 million.

  • Altimmune's Interest & Investment Income rose 27.02% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year decrease of 21.22%. This contributed to the annual value of $8.1 million for FY2024, which is 9.84% up from last year.
  • Latest data reveals that Altimmune reported Interest & Investment Income of $2.4 million as of Q3 2025, which was up 114.31% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Altimmune's Interest & Investment Income registered a high of $2.4 million during Q3 2025, and its lowest value of $13,000 during Q3 2021.
  • For the 3-year period, Altimmune's Interest & Investment Income averaged around $1.9 million, with its median value being $1.9 million (2023).
  • In the last 5 years, Altimmune's Interest & Investment Income tumbled by 72.29% in 2021 and then skyrocketed by 8,000.00% in 2022.
  • Over the past 5 years, Altimmune's Interest & Investment Income (Quarterly) stood at $115,000 in 2021, then surged by 1,176.52% to $1.5 million in 2022, then skyrocketed by 33.79% to $2.0 million in 2023, then fell by 20.11% to $1.6 million in 2024, then climbed by 27.02% to $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q3 2025, $1.1 million for Q2 2025, and $1.5 million during Q1 2025.